| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H23BrFNO2 |
| Molecular Weight | 420.315 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C3=CC=C(Br)C=C3
InChI
InChIKey=RKLNONIVDFXQRX-UHFFFAOYSA-N
InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
| Molecular Formula | C21H23BrFNO2 |
| Molecular Weight | 420.315 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Bromperidol decanoate is a long-acting antipsychotic medication used in at least Belgium, Germany, Italy, and the Netherlands. In clinical trials, Bromperidol decanoate was effective in the treatment of residual schizophrenia, with significant differences between before and after treatment ratings for symptoms. The preparation seems to be less potent than other depot antipsychotics (such as fluphenazine and haloperidol decanoate) and better than placebo injection. If bromperidol decanoate is available to the clinician it may be a viable choice, especially when there are reasons not to use fluphenazine or haloperidol decanoate.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Oral Schizophrenia:
Adult: 1-15 mg daily, up to 50 mg daily.
Intramuscular Schizophrenia:
Adult: Long-term therapy: Up to 300 mg every 4 wk via deep inj.
Intramuscular Psychoses:
Adult: Long-term therapy: Up to 300 mg every 4 wk via deep inj.
Oral Psychoses:
Adult: 1-15 mg daily, up to 50 mg daily.
Route of Administration:
Other
